Form 4: BeOne Medicines GC Sells Shares Under 10b5-1 Plan

BeOne Medicines' SVP and General Counsel, Lee Chan Henry, executed pre-planned sales of American Depositary Shares following option exercises on September 10, 2025.

Summary

• Lee Chan Henry, SVP and General Counsel of BeOne Medicines Ltd., engaged in multiple transactions involving company securities on September 10, 2025.
• Exercised share options to acquire a total of 115,622 ordinary shares, which correspond to 8,894 American Depositary Shares (ADSs).
• Sold a total of 10,006 American Depositary Shares (ADSs) at weighted average prices ranging from $324.49 to $327.93.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on May 14, 2025.
• Following these transactions, the reporting person directly owns 237,562 Ordinary Shares and retains 390,062 unexercised share options with various vesting schedules.

Sentiment

Score: 5

Explanation: A neutral score as this is a routine insider transaction (option exercise and sale) executed under a pre-planned 10b5-1 program, which is not inherently positive or negative for the company's prospects. It reflects an executive's personal financial planning.

Positives

• The sales were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new negative information.
• The reporting person still holds a significant number of ordinary shares (237,562) and unexercised options (390,062), demonstrating continued alignment with shareholder interests.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market as it reduces the insider's direct equity exposure.

Future Outlook

The filing does not contain forward-looking statements or guidance beyond the vesting schedules of remaining options.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity and does not provide information relevant to broader industry trends or competitive analysis. It reflects an individual executive's compensation and liquidity management.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of insider transactions.
• There are no specific company or project results to compare against global benchmarks or competitors.
• The use of a Rule 10b5-1 plan is a common practice for executives to manage stock sales in compliance with insider trading regulations.

Stakeholder Impact

• Shareholders: The sale by an executive could be perceived as a slight negative, but the pre-planned nature mitigates concerns. The executive still holds a substantial number of shares and options.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Continued vesting of remaining share options according to their respective schedules.
• Potential future sales or exercises by the reporting person, possibly under the existing or new 10b5-1 plans.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving option exercises and subsequent sales under a Rule 10b5-1 plan. Such pre-planned sales are common for executives managing their compensation and liquidity and do not typically signal a change in the company's fundamental outlook. The executive retains significant equity exposure, suggesting continued alignment with shareholder interests. Therefore, the filing itself does not provide a basis for a change in investment recommendation.

Keywords

BeOne Medicines, ONC, Form 4, Insider Trading, Stock Sale, Option Exercise, Rule 10b5-1, American Depositary Shares, Executive Compensation